Delwen L Franzen

Dr. Delwen L Franzen

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2015 in Journal of Neurophysiology
Verified
Journal Article
Open access
PDF file
DFDelwen L Franzen
Delwen L Franzen
SGSarah A. Gleiss
Sarah A. Gleiss
CBChristina Berger
Christina Berger
FKFranziska S. Kümpfbeck
Franziska S. Kümpfbeck
JAJulian J. Ammer
Julian J. Ammer
FFFelix Felmy
Felix Felmy
Passive and active membrane properties determine the voltage responses of neurons. Within the auditory brain stem, refinements in these intrinsic properties during late postnatal development usually generate short integration times and precise action-potential generation. This developmentally acquired temporal precision is crucial for auditory signal processing. How the interactions of these intrinsic properties develop in concert to enable auditory neurons to transfer information with high temporal precision has not yet been elucidated in detail. Here, we show how the developmental interaction of intrinsic membrane parameters generates high firing precision. We performed in vitro recordings from neurons of postnatal days 9–28 in the ventral nucleus of the lateral lemniscus of Mongolian gerbils, an auditory brain stem structure that converts excitatory to inhibitory information with high temporal precision. During this developmental period, the input resistance and capacitance decrease, and action potentials acquire faster kinetics and enhanced precision. Depending on the stimulation time course, the input resistance and capacitance contribute differentially to action-potential thresholds. The decrease in input resistance, however, is sufficient to explain the enhanced action-potential precision. Alterations in passive membrane properties also interact with a developmental change in potassium currents to generate the emergence of the mature firing pattern, characteristic of coincidence-detector neurons. Cholinergic receptor-mediated depolarizations further modulate this intrinsic excitability profile by eliciting changes in the threshold and firing pattern, irrespective of the developmental stage. Thus our findings reveal how intrinsic membrane properties interact developmentally to promote temporally precise information processing.

16 January 2020 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
DFDelwen L Franzen
Delwen L Franzen
SGSarah A. Gleiss
Sarah A. Gleiss
CKChristian J. Kellner
Christian J. Kellner
NKNikolaos Kladisios
Nikolaos Kladisios
FFFelix Felmy
Felix Felmy
The development of sensory circuits is partially guided by sensory experience. In the medial superior olive (MSO), these refinements generate precise coincidence detection to localize sounds in the azimuthal plane. Glycinergic inhibitory inputs to the MSO, which tune the sensitivity to interaural time differences, undergo substantial structural and functional refinements after hearing onset. Whether excitation and calcium signaling in the MSO are similarly affected by the onset of acoustic experience is unresolved. To assess the time window and mechanism of excitatory and calcium-dependent refinements during late postnatal development, we quantified EPSCs and calcium entry in MSO neurons of Mongolian gerbils of either sex raised in a normal and in an activity altered, omnidirectional white noise environment. Global dendritic calcium transients elicited by action potentials disappeared rapidly after hearing onset. Local synaptic calcium transients decreased, leaving a GluR2 lacking AMPAR-mediated influx as the only activity-dependent source in adulthood. Exposure to omnidirectional white noise accelerated the decrease in calcium entry, leaving membrane properties unaffected. Thus, sound-driven activity accelerates the excitatory refinement and shortens the period of activity-dependent calcium signaling around hearing onset. Together with earlier reports, our findings highlight that excitation, inhibition, and biophysical properties are differentially sensitive to distinct features of sensory experience.SIGNIFICANCE STATEMENTNeurons in the medial superior olive, an ultra-fast coincidence detector for sound source localization, acquire their specialized function through refinements during late postnatal development. The refinement of inhibitory inputs that convey sensitivity to relevant interaural time differences is instructed by the experience of sound localization cues. Which cues instruct the refinement of excitatory inputs, calcium signaling, and biophysical properties is unknown. Here we demonstrate a time window for activity- and calcium-dependent refinements limited to shortly after hearing onset. Exposure to omnidirectional white noise, which suppresses sound localization cues but increases overall activity, accelerates the refinement of calcium signaling and excitatory inputs without affecting biophysical membrane properties. Thus, the refinement of excitation, inhibition, and intrinsic properties is instructed by distinct cues.

20 January 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
SWSarah Weschke
Sarah Weschke
DFDelwen L Franzen
Delwen L Franzen
ASAnna Karolina Sierawska
Anna Karolina Sierawska
LBLea-Sophie Bonde
Lea-Sophie Bonde
DSDaniel Strech
Daniel Strech
SSSusanne Gabriele Schorr
Susanne Gabriele Schorr
Objectives To evaluate the extent and quality of patient involvement reporting in examples of current practice in health research. Design Mixed-methods study. We used a targeted search strategy across three cohorts to identify health research publications that reported patient involvement: original research articles published in 2019 in the British Medical Journal (BMJ), articles listed in the Patient-Centered Outcomes Research Institute (PCORI) database (2019), and articles citing the GRIPP2 (Guidance for Reporting Involvement of Patients and Public) reporting checklist for patient involvement or a critical appraisal guideline for user involvement. Publications were coded according to three coding schemes: ‘phase of involvement’, the GRIPP2-Short Form (GRIPP2-SF) reporting checklist and the critical appraisal guideline. Outcome measures The phase of the study in which patients were actively involved. For the BMJ sample, the proportion of publications that reported patient involvement. The quality of reporting based on the GRIPP2-SF reporting guideline. The quality of patient involvement based on the critical appraisal guideline. Quantitative and qualitative results are reported. Results We included 86 publications that reported patient involvement. Patients were most frequently involved in study design (90% of publications, n=77), followed by study conduct (71%, n=61) and dissemination (42%, n=36). Reporting of patient involvement was often incomplete, for example, only 40% of publications (n=34) reported the aim of patient involvement. While the methods (57%, n=49) and results (59%, n=51) of involvement were reported more frequently, reporting was often unspecific and the influence of patients’ input remained vague. Therefore, a systematic assessment of the quality and impact of patient involvement according to the critical appraisal guideline was not feasible across samples. Conclusions As patient involvement is increasingly seen as an integral part of the research process and requested by funding bodies, it is essential that researchers receive specific guidance on how to report patient involvement activities. Complete reporting builds the foundation for assessing the quality of patient involvement and its impact on research.

21 March 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
TWTracey L. Weissgerber
Tracey L. Weissgerber
MGMalgorzata Gazda
Malgorzata Gazda
GNGustav Nilsonne
Gustav Nilsonne
GRGerben ter Riet
Gerben ter Riet
KCKelly D. Cobey
Kelly D. Cobey
MMMalcolm R. Macleod
Malcolm R. Macleod
Understanding the provenance and quality of methods is essential for responsible reuse of FAIR data Correspondence separate, essential research products. A vibrant open methods community is needed to champion this, such as exists for open data and open code. FAIR data should increase the opportunities for secondary analysis. Previously, these analyses have been conducted by, or in close collaboration with, the researchers who collected the data, or involved large, well-documented, publicly available datasets, such as population studies or government registries. FAIR data sharing can further expand the number and types of available datasets, while reducing the need for collaboration between the data depositor and the data user or re-user, but this will require changes to data deposition and reuse strategies. We encourage those with relevant expertise who are interested in contributing to principles for responsible data reuse to contact us.

1 February 2025 in Journal of Clinical Epidemiology
Verified
Journal Article
Open access
GNGustav Nilsonne
Gustav Nilsonne
SWSusanne Wieschowski
Susanne Wieschowski
NDNicholas J. DeVito
Nicholas J. DeVito
MSMaia Salholz-Hillel
Maia Salholz-Hillel
LALove Ahnström
Love Ahnström
CACathrine Axfors
Cathrine Axfors
To systematically evaluate timely reporting of clinical trial results at medical universities and university hospitals in the Nordic countries. In this cross-sectional study, we included trials (regardless of intervention) registered in the European Union (EU) Clinical Trials Registry and/or ClinicalTrials.gov, completed 2016-2019 and led by a university with medical faculty or university hospital in Denmark, Finland, Iceland, Norway, or Sweden. We identified summary results posted at the trial registries and conducted systematic manual searches for results publications (eg, journal articles, preprints). We present proportions with 95% confidence intervals (CI) and medians with interquartile range (IQR). https://osf.io/wua3r. Among 2112 included clinical trials, 1650 (78.1%, 95% CI 76.3%-79.8%) reported any results during our follow-up; 1097 (51.9%, 95% CI 49.8%-54.1%) reported any results within 2 years of the global completion date; and 48 (2.3%, 95% CI 1.7%-3.0%) posted summary results in the registry within 1 year. The median time from global completion date to results reporting was 690 days (IQR 1103). 856/1681 (50.9%) of ClinicalTrials.gov registrations were prospective. Denmark contributed approximately half of all trials. Reporting performance varied widely between institutions. Missing and delayed results reporting of academically led clinical trials are a pervasive problem in the Nordic countries. We relied on trial registry information, which can be incomplete. Institutions, funders, and policymakers need to support trial teams, ensure regulation adherence, and secure trial reporting before results are permanently lost. Reporting of results from clinical trials is necessary for evidence-based clinical decision-making. We followed up reporting of clinical trials in the Nordic countries sponsored by medical universities and university hospitals. Of 2112 studies completed 2016-2019 in two major trials registries, about half reported results in any form within 24 months, and more than one in five did not report results at all. These results show that there is a need for improvement in the reporting of Nordic clinical trials.

21 March 2023 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
DFDelwen L Franzen
Delwen L Franzen
BCBenjamin Gregory Carlisle
Benjamin Gregory Carlisle
MSMaia Salholz-Hillel
Maia Salholz-Hillel
NRNico Riedel
Nico Riedel
DSDaniel Strech
Daniel Strech
Background: University Medical Centers (UMCs) must do their part for clinical trial transparency by fostering practices such as prospective registration, timely results reporting, and open access. However, research institutions are often unaware of their performance on these practices. Baseline assessments of these practices would highlight where there is room for change and empower UMCs to support improvement. We performed a status quo analysis of established clinical trial registration and reporting practices at German UMCs and developed a dashboard to communicate these baseline assessments with UMC leadership and the wider research community. Methods and findings: We developed and applied a semiautomated approach to assess adherence to established transparency practices in a cohort of interventional trials and associated results publications. Trials were registered in ClinicalTrials.gov or the German Clinical Trials Register (DRKS), led by a German UMC, and reported as complete between 2009 and 2017. To assess adherence to transparency practices, we identified results publications associated to trials and applied automated methods at the level of registry data (e.g., prospective registration) and publications (e.g., open access). We also obtained summary results reporting rates of due trials registered in the EU Clinical Trials Register (EUCTR) and conducted at German UMCs from the EU Trials Tracker. We developed an interactive dashboard to display these results across all UMCs and at the level of single UMCs. Our study included and assessed 2,895 interventional trials led by 35 German UMCs. Across all UMCs, prospective registration increased from 33% (n = 58/178) to 75% (n = 144/193) for trials registered in ClinicalTrials.gov and from 0% (n = 0/44) to 79% (n = 19/24) for trials registered in DRKS over the period considered. Of trials with a results publication, 38% (n = 714/1,895) reported the trial registration number in the publication In turn, 58% (n = 861/1,493) of trials registered in ClinicalTrials.gov and 23% (n = 111/474) of trials registered in DRKS linked the publication in the registration. In contrast to recent increases in summary results reporting of drug trials in the EUCTR, 8% (n = 191/2,253) and 3% (n = 20/642) of due trials registered in ClinicalTrials.gov and DRKS, respectively, had summary results in the registry. Across trial completion years, timely results reporting (within 2 years of trial completion) as a manuscript publication or as summary results was 41% (n = 1,198/2,892). The proportion of openly accessible trial publications steadily increased from 42% (n = 16/38) to 74% (n = 72/97) over the period considered. A limitation of this study is that some of the methods used to assess the transparency practices in this dashboard rely on registry data being accurate and up-to-date. Conclusions: In this study, we observed that it is feasible to assess and inform individual UMCs on their performance on clinical trial transparency in a reproducible and publicly accessible way. Beyond helping institutions assess how they perform in relation to mandates or their institutional policy, the dashboard may inform interventions to increase the uptake of clinical transparency practices and serve to evaluate the impact of these interventions.